The operational challenges of making patient-specific cell therapies require careful consideration. Choosing the manufacturing model that fits the healthcare infrastructure, the logistical requirements, and the market environment of the specific project is key. The post No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechn…
Nature Immunology, Published online: 08 September 2026; doi:10.1038/s41590-026-02642-z Here the authors show that T cell activation within tumors triggers tumor clearance that is independent of tumor antigen recognition and occurs via a paracrine mechanism involving effector cytokines, nitric oxide, leukocyte recruitment and innate immune cells.
Nature Immunology, Published online: 08 September 2026; doi:10.1038/s41590-026-02650-z Chimeric antigen receptors (CARs) have revolutionized engineered cell therapies for cancer. Impressive anti-tumor effects have now been achieved by fitting CARs onto fused macrophage–neutrophil hybrid syncytial, with a promising outlook for stand-alone and combination therapies.
EMEA Office
Louizalaan 489
1050 Brussels
Belgium
Neuroplast is revolutionizing the treatment of neurodegenerative diseases. By 2050, 115 million people will suffer from these debilitating diseases for which no effective treatments exist today. Its cell therapy Neuro-Cells® is a radically different treatment approach as it consists of a mixture of cells, does not involve genetic manipulation, and …
Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy […] The post 3 cell therapy companies doing well: Vertex, Vericel, …
